RT Journal Article
SR Electronic
T1 Longevity of seropositivity and neutralizing titers among SARS-CoV-2 infected individuals after 4 months from baseline: a population-based study in the province of Trento
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.11.20229062
DO 10.1101/2020.11.11.20229062
A1 Stefanelli, Paola
A1 Bella, Antonino
A1 Fedele, Giorgio
A1 Fiore, Stefano
A1 Pancheri, Serena
A1 Benedetti, Eleonora
A1 Fabiani, Concetta
A1 Leone, Pasqualina
A1 Vacca, Paola
A1 Schiavoni, Ilaria
A1 Neri, Arianna
A1 Carannante, Anna
A1 Simmaco, Maurizio
A1 Santino, Iolanda
A1 Zuccali, Maria Grazia
A1 Bizzarri, Giancarlo
A1 Magnoni, Rosa
A1 Benetollo, Pier Paolo
A1 Brusaferro, Silvio
A1 Rezza, Giovanni
A1 Ferro, Antonio
YR 2020
UL http://medrxiv.org/content/early/2020/11/16/2020.11.11.20229062.abstract
AB Background There are conflicting results about the duration of antibodies induced by SARS-CoV-2, but several studies show a rapid decay in a few months after infection. To evaluate antibody decline, we re-evaluated the presence of anti-SARS-CoV-2 antibodies among individuals found seropositive in a first population survey conducted 4 months before.Methods All individuals above ten years of age resident in 5 municipalities of the Autonomous Province of Trento, northern Italy, who resulted IgG positive for anti-SARS-CoV-2 nucleocapsid (NC) antibodies in a serosurvey conducted on May 2020 were retested after 4 months. Anti-SARS-CoV-2 antibodies were detected using the Abbott SARS-CoV-2 IgG assay (Abbott Diagnostics, USA) detecting anti-NC antibodies. Samples that gave a negative result were re-tested using the same test plus Liaison SARS-CoV-2 IgG assay (DiaSorin, Italy) to assess anti-spike (S) S1/S2 IgG antibodies. Seroprevalence was calculated as the proportion of positive people on the total number of tested. A neutralizing assay was performed on a subgroup of formerly positives sera using fifty-percent tissue culture infective dose (TCID50) as endpoint dilution to produce a cytopathic effect in 50% of inoculated Vero E6 cells culture. In all the analyses a p value < 0.05 were considered statistically significant. Statistical analysis was performed by STATA version 16.1 (STATA Corp., College Station, Texas, USA).Findings Overall, 1159 out of 1402 initially anti-NC seropositive participants were enrolled in the study. Of them, 480 (41.1%) became seronegative for anti-NC IgG antibodies. When 479 negative sera were tested for anti-S IgG, 373 samples (77.9%) resulted positives. A functional neutralization assay was performed on 106 sera showing high concordance with anti-S antibodies positivity.Interpretation A decline of anti-NC IgG values was recorded 4 months after the first evaluation. Worth of note, a high proportion of anti-NC seronegative individuals were positive for anti-spike IgG antibodies, which appear to persist longer and to better correlate with neutralization activity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAPSS sustained the expenses for the IgG assays on collected sera.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval Informed consensus for blood collection was obtained from all the participants. The study was approved by the Ethical Committee of the ISS (Prot. PRE BIO CE n.15997, 04.05.2020). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNA